CARDIAC-ARREST AND SUDDEN-DEATH IN PATIENTS TREATED WITH AMIODARONE FOR SUSTAINED VENTRICULAR-TACHYCARDIA OR VENTRICULAR-FIBRILLATION - RISK STRATIFICATION BASED ON CLINICAL-VARIABLES

Multivariate analysis of 11 clinical variables was performed in 104 patients with sustained, symptomatic ventricular tachycardia (VT) or ventricular fibrillation treated with amiodarone to determine variables predictive of subsequent cardiac arrest or sudden death. Twenty-five patients (24%) had fatal or nonfatal cardiac arrest after 7.3 .+-. 6.2 mo. of therapy. Multivariate analysis identified an ejection fraction of less than 0.40, syncope or cardiac arrest before amiodarone therapy and VT (3 or more consecutive ventricular premature complexes) during predischarge ambulatory ECG monitoring as variables associated with a high risk of subsequent fatal or nonfatal cardiac arrest (P < 0.03). Patients who had these 3 clinical variables had a much higher predicted incidence of cardiac arrest at 6 mo. (62%) and 12 mo. (76%) than did patients with an ejection fraction greater than 0.40, without syncope or cardiac arrest before amiodarone therapy and without VT during predischarge ambulatory ECG monitoring (2% and 5%, respectively) (P < 0.02). Risk stratification using clinical variables can predict which patients are at high risk of recurrent cardiac arrest or sudden death during amiodarone therapy.